Autoimmune comorbidity in demyelinating diseases of the central nervous system Samarina

Autoimmune diseases (ADs) are a broad group of phenotypically heterogeneous conditions characterized by both unique and common clinical and immunological manifestations, with varying rates of progression and responses to pathogenetic therapy. More than 10 per cent of the global population suffers from at least one of ADs, and in recent decades there has been a worldwide trend towards an increase in the number of cooccurring autoimmune conditions, particularly in regions and countries with a high level of socio-demographic development. Given their shared risk factors and immunopathological mechanisms, demyelinating diseases of the central nervous system are associated with an increased likelihood of developing a concomitant ADs, which may unpredictably influence the course of the demyelinating process and the choice of optimal treatment. This review examines the co-occurrence of multiple sclerosis and neuromyelitis optica spectrum disorders (NMOSD) with anti-aquaporin-4 antibodies (AQP4) with the most common associated ADs, and summarises the evidence regarding the preferred therapeutic approaches in each specific case.

1. Dinse GE, Parks CG, Weinberg CR, et al. Increasing Prevalence of Antinuclear Antibodies in the United States. Arthritis Rheum. 2020 Jun;72(6):1026-35. doi: 10.1002/art.41214

2. Conrad N, Misra S, Verbakel J, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a populationbased cohort study of 22 million individuals in the UK. Lancet. 2023;401:1878-90.

3. Leal Rato M, Santos M, de Sa J, Ferreira J. Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective cohort study. J Neuroimmunol. 2023 Dec 15;385:578226. doi: 10.1016/j.jneuroim.2023.578226

4. Aslan D, Bourabia S, Kowall B, et al. The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study. J Neurol. 2025 Sep 3;272(9):607. doi: 10.1007/s00415-025-13351-2

5. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol. 2006 Nov;5(11):924-31. doi: 10.1016/S1474-4422(06)70552-X

6. Carnero Contentti E, Lopez PA, Pettinicchi JP, et al. Neuromyelitis optica spectrum disorders with and without associated autoimmune diseases. Neurol Sci. 2023 May;44(5):1731-7. doi: 10.1007/s10072-023-06611-4

7. Wingerchuk DM, Lucchinetti CF. Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2022 Aug 18;387(7):631-9. doi: 10.1056/NEJMra1904655

8. Liu Q, Jiang Y, Frisell T, et al. Shared aetiology underlying multiple sclerosis and other immune mediated inflammatory diseases: Swedish familial co-aggregation and large-scale genetic correlation analyses. J Autoimmun. 2024 Sep;148:103294. doi: 10.1016/j.jaut.2024.103294

9. Liu CY, Tung TH, Lee CY, et al. Association of Multiple Sclerosis with Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies. Am J Clin Dermatol. 2019 Apr; 20(2):201-8. doi: 10.1007/s40257-018-0399-9

10. Miron G, Gurevich M, Baum S, et al. Psoriasis comorbidity affects multiple sclerosis neurological progression: a retrospective casecontrol analysis. J Eur Acad Dermatol Venereol. 2017;31(12):2055-61. doi: 10.1111/jdv.14403

11. Zivadinov R, Raj B, Ramanathan M, et al. Autoimmune comorbidities are associated with brain injury in multiple sclerosis. AJNR Am J Neuroradiol. 2016;37(6):1010-16. doi: 10.3174/ajnr.A4681

12. Miele G, Sparaco M, Maida E, et al. Clinical implications for the association of psoriasis and multiple sclerosis: an observational study. Neurol Sci. 2024 Nov;45(11):5395- 403. doi: 10.1007/s10072-024-07616-3

13. Havrdova E, Belova A, Goloborodko A, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016 Jul; 263(7):1287-95. doi: 10.1007/s00415-016-8128-x

14. Di Tullio F, Odorici G, Lasagni C, et al. Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis. Dermatol Ther. 2020 Nov;33(6):e13943. doi: 10.1111/dth.13943

15. Megna M, Noto M, Fabbrocini G, Fornaro L. A case of psoriasis and multiple sclerosis succesfully treated with concomitant fingolimod and secukinumab. Australas J Dermatol. 2023 Feb;64(1):e100-e102. doi: 10.1111/ajd.13983

16. Kougkas N, Kruger-Krasagakis S, Papadaki E, Mastorodemos VC. Successful treatment of highly active multiple sclerosis and psoriasis exacerbation with natalizumab and secukinumab combination. A case report and literature review. Neuroimmunol Rep. 2022;2:100054. doi: 10.1016/j.nerep.2022.100054

17. Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014 Dec 6;384(9959):2036-45. doi: 10.1016/S0140-6736(14)60803-5

18. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996 Dec;47(6):1531- 4. doi: 10.1212/wnl.47.6.1531

19. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 1999 Aug 11;53(3):457-65.

20. Perez-De-Lis M, Retamozo S, Flores-Chavez A, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opinion Drug Saf. 2017 Nov; 16(11):1255-71. doi: 10.1080/14740338.2017.1372421

21. Kim TH, Park J, Jo H, et al. Global burden of TNF-α inhibitors associated demyelinating diseases: A global disproportionality analysis. Medicine (Baltimore). 2025 Nov 21;104(47):e46040. doi: 10.1097/MD.0000000000046040

22. Lopez-Lerma I, Iranzo P, Herrero C. New-onset psoriasis in a patient treated with interferon beta-1a. Brit J Dermatol. 2009 Mar;160(3):716-7. doi: 10.1111/j.1365-2133.2008.09005.x

23. Heerfordt IM, Framke E, Windfeld-Mathiasen J, et al. Reevaluating the role of interferon-beta in psoriasis pathogenesis: A registry-based self-controlled study. J Dermatol. 2024 Aug;51(8):1113-6. doi: 10.1111/1346-8138.17338

24. Porwal MH, Patel D, Maynard M, Obeidat AZ. Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis. Mult Scler Relat Disord. 2022 Jul;63:103832. doi: 10.1016/j.msard.2022.103832

25. Wang X, Wan J, Wang M, et al. Multiple sclerosis and inflammatory bowel disease: A systematic review and meta-analysis. Ann Clin Transl Neurol. 2022 Feb;9(2):132-40. doi: 10.1002/acn3.51495

26. Nabizadeh F, Azizi A, Hejrati L, et al. Multiple sclerosis and ulcerative colitis: A systematic review and meta-analysis. Mult Scler J Exp Transl Clin. 2023 Jul 19;9(3):20552173231186516. doi: 10.1177/20552173231186516

27. Coxam B, Sheikh F, Kew H, Fraser M. Clinical profile of patients with comorbid IBD and MS, and associated service impact in England's secondary care setting: a retrospective cohort study. BMJ Open. 2025 Jun 18;15(6):e088808. doi: 10.1136/bmjopen-2024-088808

28. Zephir H, Gower-Rousseau C, Salleron J, et al. Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease. Mult Scler. 2014 Jul;20(8):1135- 9. doi: 10.1177/1352458513515081

29. Bittner S, Kriegel MA, Siegmund B, et al. Treatment Options for the Comorbidity of Multiple Sclerosis with Other Chronic Inflammatory Diseases. Dtsch Arztebl Int. 2025 Aug 8;122(16):427-32. doi: 10.3238/arztebl.m2025.0088

30. Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observerblinded endpoint study. Lancet Gastroenterol Hepatol. 2020;9(5):819-28. doi: 10.1016/S2468-1253(20)30188-6

31. Ladron Abia P, Alcala Vicente C, Martinez Delgado S, Bastida Paz G. Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis. Gastroenterol Hepatol. 2021 Feb;44(2):156-157. doi: 10.1016/j.gastrohep.2020.07.020

32. Dryden GW. Natalizumab for Moderate-toSevere Crohn's Disease. Gastroenterol Hepatol (N Y). 2008 Apr; 4(4):296.

33. Au M, Mitrev N, Leong RW, Kariyawasam V. Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease: A case report and review of literature. World J Clin Cases. 2022 Mar 16;10(8):2569-76. doi: 10.12998/wjcc.v10.i8.2569

34. Kristjansson B, Lund SH, Gröndal G, et al. Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018. Scand J Gastroenterol. 2021 Jan;56(1):46-52. doi: 10.1080/00365521.2020.1854847

35. Fresse A, Hommel C, Petitpain N, Kerschen P. Ocrelizumab-induced colitis: VigiBase disproportionality analysis, case reports and literature review. Br J Clin Pharmacol. 2026 Feb 15. doi: 10.1002/bcp.70490

36. Tolaymat S, Sharma K, Kagzi Y, Sriwastava S. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review. Mult Scler Relat Disord. 2023 Jul;75:104763. doi: 10.1016/j.msard.2023.104763

37. Ghiasian M, Rastgoo Haghi A, Borzouei S, Bawand R. Simultaneous onset of Crohn's disease and Psoriasis in a Multiple Sclerosis patient treated with Teriflunomide: A novel case report highlighting potential autoimmune interactions. Heliyon. 2024 Feb 9;10(4):e26195. doi: 10.1016/j.heliyon.2024.e26195

38. Esfahani NZ, von Geldern G, Romba MC, et al. Inflammatory colitis associated with Teriflunomide. Mult Scler Relat Disord. 2020 Nov;46:102480. doi: 10.1016/j.msard.2020.102480

39. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012 Jan 19;9:14. doi: 10.1186/1742-2094-9-14

40. Cakan M, Demirel E, Cimen B, et al. Comparison of clinical features of aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein associated disorder (MOGAD), and double seronegative NMOSD – A single center experience. J Neuroimmunol. 2025 Jun 15;403:578591. doi: 10.1016/j.jneuroim.2025.578591

41. Sami F, Sami SA, Manadan AM, Arora S. Nationwide analysis of neuromyelitis optica in systemic lupus erythematosus and Sjogren's syndrome. Clin Rheumatol. 2024 Jan;43(1):59- 65. doi: 10.1007/s10067-023-06809-z

42. Kwon S, Han KD, Jung JH, et al. Risk of Autoimmune Rheumatic Diseases in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Nationwide Cohort Study in South Korea. Mayo Clin Proc. 2025 May;100(5):801-13. doi: 10.1016/j.mayocp.2024.11.028

43. Kopp CR, Prasad CB, Naidu S, et al. Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and systemic lupus erythematosus: A systematic review of individual patient data. Lupus. 2023 Sep;32(10):1164-72. doi: 10.1177/09612033231191180

44. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012 Jan;18(1):5-10. doi: 10.1177/1352458511431077

45. Hasegawa Y, Arinuma Y, Muramatsu T, Kondou J. The pathogenic role of lupus-specific autoantibodies and Interleukin-6 on demyelination of the brainstem and spinal cord in systemic lupus erythematosus. Lupus. 2023 Mar; 32(3):401-10. doi: 10.1177/09612033231151600

46. Yamamoto M, Okuno T, Piao JL, et al. Identification of double-stranded DNA in the cerebrospinal fluid of patients with acute neuromyelitis optica spectrum disorder. J Clin Neurosci. 2023 Jan;107:129-32. doi: 10.1016/j.jocn.2022.12.005

47. Kumar A, Gupta A, Gupta P, et al. The Coexisting Neuromyelitis Optica Spectrum Disorder and Systemic Lupus Erythematosus: A Therapeutic Challenge. Mediterr J Rheumatol. 2023 Aug 8;34(3):372-6. doi: 10.31138/mjr.20230808.tc

48. Zhang S, Wang Z, Zhao J, et al. Clinical features of transverse myelitis associated with systemic lupus erythematosus. Lupus. 2020 Apr;29(4):389-97. doi: 10.1177/0961203320905668

49. Arnaud L, Ruiz-Irastorza G, Aranow C, et al. ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. Lancet Rheumatol. 2025 Jul; 7(7):e505-e518. doi: 10.1016/S2665-9913(25)00063-3

50. Sammaritano LR, Askanase A, Bermas BL, et al. American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis Rheum. 2025 Nov 4. doi: 10.1002/art.43452

51. Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosusassociated thrombotic microangiopathy. BMC Nephrol. 2020 Jun 30;21(1):245. doi: 10.1186/s12882-020-01888-5

52. Dai M, Huang C, Zhou M, et al. Dual BLyS/APRIL targeted therapy with telitacicept in rituximab-refractory SLE-associated neuromyelitis optica spectrum disorder: a case report. Front Immunol. 2025 May 26;16:1602800. doi: 10.3389/fimmu.2025.1602800

53. Akaishi T, Tarasawa K, Matsumoto Y, et al. Associations between neuromyelitis optica spectrum disorder, Sjögren's syndrome, and conditions with electrolyte disturbances. J Neurol Sci. 2023 Sep 15;452:120742. doi: 10.1016/j.jns.2023.120742

54. Akaishi T, Takahashi T, Fujihara K, et al. Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol. 2021 May;268(5):1938-44. doi: 10.1007/s00415-020-10377-6

55. Estiasari R, Matsushita T, Masaki K, et al. Comparison of clinical, immunological and neuroimaging features between anti-aquaporin-4 antibody-positive and antibody-negative Sjögren's syndrome patients with central nervous system manifestations. Mult Scler. 2012 Jun;18(6):807-16. doi: 10.1177/1352458511431727

56. Prasad CB, Kopp CR, Naidu G, et al. Overlap syndrome of anti-aquaporin 4 positive neuromyelitis optica spectrum disorder and primary Sjögren's syndrome: a systematic review of individual patient data. Rheumatol Int. 2024 Dec;44(12):2807-15. doi: 10.1007/s00296-023-05397-0

57. Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020 May;19(5):391-401. doi: 10.1016/S1474-4422(20)30070-3. Erratum in: Lancet Neurol. 2025 Dec; 24(12):e14. doi: 10.1016/S1474-4422(25)00394-1

58. Zheng X, Di J, Chen X, et al. Meta-analysis of the efficacy and safety of rituximab in the treatment of primary Sjögren's syndrome. Front Immunol. 2025 Jun 24;16:1561214. doi: 10.3389/fimmu.2025.1561214

59. Mariette X, Barone F, Baldini C, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome. JCI Insight. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030

60. Li S, Gao Y, He Y, Zhang Z. A case report of AQP4-IgG-seropositive refractory neuromyelitis optica spectrum disorder patient with Sjögren's syndrome and pancytopenia treated with inebilizumab. Front Neurol. 2024 Jun 5;15:1371515. doi: 10.3389/fneur.2024.1371515